论文部分内容阅读
萘丁美酮（ＮＡＢ）是一种新型非甾体抗炎药。为了比较研究该药与阳性对照药萘普生（ＮＡＰ）对骨关节炎（ＯＡ）的疗效和安全性，我们组织全国三个中心对ＮＡＢ和ＮＡＰ治疗ＯＡ进行了随机、双盲、多中心和平行性的Ⅱ期临床试验。结果表明，经４ｗｋ治疗后，ＮＡＢ（６０例）的总有效率为８５．００％，ＮＡＰ（６０例）的总有效率为７５．００％，两者疗效相近。ＮＡＢ的不良反应发生率为１０．００％，ＮＡＰ的不良反应发生率为２５．００％，差异显著。提示ＮＡＢ治疗ＯＡ疗效明显，与ＮＡＰ作用相近，但不良反应发生率明显低于ＮＡＰ。
Nabumetone (NAB) is a novel non-steroidal anti-inflammatory drug. To compare the efficacy and safety of this drug with the positive control naproxen (NAP) in the treatment of osteoarthritis (OA), we conducted a randomized, double-blind, multicentre, and multicenter trial of NAB and NAP in three centers across the country Parallel phase Ⅱ clinical trial. The results showed that after 4 weeks of treatment, the total effective rate of NAB (60 cases) was 85.00%, and the total effective rate of NAP (60 cases) was 75.00%. The curative effect was similar between the two groups. The incidence of adverse reactions in NAB was 10.00%, and the incidence of NAP in adverse reactions was 25.00%. The difference was significant. Prompt NAB treatment of OA obvious effect, and NAP role similar, but the incidence of adverse reactions was significantly lower than NAP.